Table 4. Adverse Events.

Adverse Events	LY-CoV555 (N=309)				Placebo (N=143)
	700 mg (N=101)	2800 mg (N=107)	7000 mg (N=101)	Pooled Doses (N=309)
	number of patients (percent)
Serious adverse events*	0	0	0	0	1 (0.7)
Adverse events
Any	24 (23.8)	23 (21.5)	22 (21.8)	69 (22.3)	35 (24.5)
Mild	16 (15.8)	18 (16.8)	10 (9.9)	44 (14.2)	18 (12.6)
Moderate	7 (6.9)	3 (2.8)	8 (7.9)	18 (5.8)	16 (11.2)
Severe	0	2 (1.9)	3 (3.0)	5 (1.6)	1 (0.7)
Missing data	1 (1.0)	0	1 (1.0)	2 (0.6)	0
Adverse events according to preferred term†
Nausea	3 (3.0)	4 (3.7)	5 (5.0)	12 (3.9)	5 (3.5)
Diarrhea	1 (1.0)	2 (1.9)	7 (6.9)	10 (3.2)	7 (4.9)
Dizziness	4 (4.0)	3 (2.8)	3 (3.0)	10 (3.2)	3 (2.1)
Headache	3 (3.0)	2 (1.9)	0	5 (1.6)	3 (2.1)
Pruritus	2 (2.0)	3 (2.8)	0	5 (1.6)	1 (0.7)
Vomiting	1 (1.0)	3 (2.8)	1 (1.0)	5 (1.6)	4 (2.8)
Chills	0	1 (0.9)	3 (3.0)	4 (1.3)	0
Pyrexia	1 (1.0)	2 (1.9)	1 (1.0)	4 (1.3)	1 (0.7)
Chest discomfort	1 (1.0)	1 (0.9)	1 (1.0)	3 (1.0)	1 (0.7)
Fatigue	0	1 (0.9)	2 (2.0)	3 (1.0)	0
Hypertension	1 (1.0)	0	2 (2.0)	3 (1.0)	0
Lipase increased	1 (1.0)	0	2 (2.0)	3 (1.0)	0
Thrombocytosis	1 (1.0)	2 (1.9)	0	3 (1.0)	0
Blood pressure increased	2 (2.0)	0	0	2 (0.6)	0
Chest pain	1 (1.0)	1 (0.9)	0	2 (0.6)	0
Dyspepsia	1 (1.0)	0	1 (1.0)	2 (0.6)	0
Hypersensitivity	1 (1.0)	1 (0.9)	0	2 (0.6)	1 (0.7)
Insomnia	0	1 (0.9)	1 (1.0)	2 (0.6)	0
Nasal congestion	1 (1.0)	1 (0.9)	0	2 (0.6)	1 (0.7)
Rash	1 (1.0)	0	1 (1.0)	2 (0.6)	1 (0.7)
Syncope	0	1 (0.9)	1 (1.0)	2 (0.6)	1 (0.7)

^*The serious adverse event in the placebo group was upper abdominal pain. There were no deaths during the trial.

^†The preferred terms were defined according to the Medical Dictionary for Regulatory Activities, version 23.0.